 By John Vandermosten, CFA NASDAQ:AZRX On August 11, 2020, AzurRx NASDAQ:AZRX management provided an update for the combination Phase II trial that is evaluating MS1819 in combination with porcine enzyme replacement therapy PERT. Despite only representing five individuals, the results demonstrated a nine point improvement in the coefficient of fat absorption CFA and improvements across the 